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OBJECTIVE 
To present the immediate results and assess the 
clinical and hemodynamic performance of stentless bovine 
pericardial bioprostheses in aortic position. 
METHODS 
Twenty patients were operated who were indicated for 
surgery for valve replacement with biological prostesis. 
Eleven patients were male; sixteen had aortic stenosis; 
four, insufficiency; the mean age was 66.3 ± 8.8 
years. The surgical technique used was subcoronary 
implant. Associated procedures were performed 
in five patients. Postoperative morbidity,mortality 
and hemodynamic performance were assessed on 
transthoracic echocardiogram.
RESULTS 
Mean time of cardiopulmonary bypass was 136.5 
± 24.41 minutes and mean anoxic time was 105.2 ± 
21.62 minutes. Hospital mortality was 5% (one patient). 
Mean time of intensive care unit stay was 3.65 ± 3.23 
days. Mean postoperatively transvalvular gradient was 
was 25.39 ± 7.82 mmHg. Left ventricle ejection fraction 
was 67 ± 13.49% preoperatively and 63.24 ± 16.06% 
postoperatively (p = 0.45). Eleven patients did not present 
any degree of valve regurgitation, eight presented mild 
regurgitation and one ,mild to moderate regurgitation. 
CONCLUSION 
Stentless prostheses can be used for the surgical 
tratment of aortic valve diseases, with in hospital mortality 
and morbidity similar to the mortality and morbidity 
described in the literature for similar procedures, with 
satisfactory hemodynamic performance. 
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Despite the advancements made in the last decade 
as regards valve surgery, we can say that no ideal valve 
replacement exists to date, and as the possibility of 
preserving aortic valves is infrequent, surgical treatment 
almost always implies valve replacement. 
The most frequently used prostheses – biological and 
mechanical – present, respectively, limited durability and 
requirement of the use of oral anticoagulants. Additionally, 
these prostheses, because they are supported by rigid 
rings, generate residual pressure gradients between the 
left ventricle and the aorta, which may be a problem, 
especially for patients with small aortic ring and in those 
with major myocardial hypertrophy1,2. 
It is a true challenge to fi nd a near ideal aortic valve 
replacement which presents high durability, with no need 
of using oral anticoagulants and with a mechanism of 
functioning that is similar to the normal aortic valve. 
Although the use of cryopreserved homografts yields 
satisfactory results3-5, their use is restricted to few centers 
and they’re diffi cult to obtain. For these reasons the 
demand for treatment of valve lesions will hardly be met 
by homografts.
In 1987, David et al6 started to develop stentless 
heterologous prostheses which are supported by the aorta 
wall itself. Because their anatomy is very similar to that of 
normal aortic valves and because these prostheses lack 
a supporting ring for valves or leafl ets, they generate a 
smaller pressure gradient between the left ventricle and 
the aorta and, as a result, there is less hemodynamic 
stress, which may translate into longer durability2,7,8. 
The objective of this study is to analyze hospital 
morbidity and mortality with the use of stentless 
heterologous bovine pericardial bioprostheses in aortic 
position and their hemodynamic performance. 
METHODS
We considered twenty patients with severe aortic valve 
lesion to receive stentless heterologous bovine pericardial 
bioprostheses (produced by Braile Biomédica®). These 
patients were referred for surgery but presented counter-
indication for mechanical prostheses. From this study 
we excluded patients with major comorbidities such 
as severe COPD, dialytic renal failure, peripheral 
arteriopathy and reoperations. The use of these 
bioprostheses was authorized by the rules of the Medical 
Ethics Committee. 
Eleven (55%) patients were male, sixteen (80%) 
patients presented aortic stenosis, and four (20%) 
presented aortic insuffi ciency . The age varied between 31 
to 75 years, with a mean age of 66.3 ± 8.8 years. Of the 
patients with aortic insuffi ciency, three were in functional 
class (FC) III, and one was in FC II. Of the patients with 
aortic stenosis, nine had symptoms of syncope, and all 
presented precordialgia, classifi ed according the criteria 
of the CCS (Canadian Cardiovascular Society) in FC I, two 
patients, FC II, fi ve patients, FC III, seven patients, and 
FC IV, two patients. 
Two patients were diagnosed with atherosclerotic 
coronary disease, whose lesions caused a lumen 
obstruction greater than 60%. 
Critical mitral stenosis was diagnosed in two patients, 
one with a valve area of 0.7 cm2, and the other with 
a valve area of 1.2 cm2. One patient presented mitral 
insuffi ciency associated with aortic lesion. 
Left ventricular function was normal in fi fteen (75%) 
of the patients; four (20%) presented mild to moderate 
dysfunction and only one patient presented severe 
ventricular dysfunction (ejection fraction equal to 30%). 
The patients were operated by longitudinal median 
sternotomy and the cardiopulmonary bypass circuit was 
installed with cannulation of the aorta and right atrium. 
The surgery was performed under hypothermia at 28°.
Myocardial protection was effected using anterograde 
hypothermic blood cardioplegia, by directly cannulating 
the coronary ostia. The cardioplegic solution was 
composed of the perfusate blood itself, cooled to 4°, with 
potassium (15 mEq/l) only in the fi rst induction, and in 
subsequent doses (approximately every twenty minutes), 
only cooled perfusate blood. 
Stentless prosthesis implant - The use of this 
type of prosthesis requires aortotomy 1 cm above the 
sinotubular junction.
The technique employed to implant the prosthesis 
was the subcoronary technique, in which two planes of 
suture are performed. The fi rst with simple stitches with 
Ethibond® 4-0 sutures, passed around the valve annulus, 
with four to fi ve sutures per commissure, totalling between 
12 to 15 sutures. These sutures should be positioned on 
the same plane, and should not follow the aortic ring until 
the commissure. Pericardial stentless bioprostheses come 
in tubular form and we have to section the commissures 
to perform the second plane of sutures.
After measuring the sinotubular junction and choosing 
the prosthesis, the sutures of the fi rst plane are passed 
and the prosthesis is lowered to its position close to the 
valve annulus and the sutures are tied (fi g. 1). 
After lowering the prosthesis until it reached the level 
of the aortic annulus, we positioned the commissures. To 
this effect, we used U-shaped transfi xing Prolene® 5-0 
sutures, placed equidistantly from the three commissures. 
In order to facilitate the exposure of the valve and of the 
sinuses of Valsalva, and to perform the second plane of 
suture, we did not tie those commissural stitches. 
Then the second suture was continuously performed 
on the subcoronary plane, with Prolene® 4-0, starting 
in the inferior part of the coronary ostia, passing around 
them and then up towards the commissures. 
This suture was performed in the three commissures 
and in the end the U sutures with Prolene® 5-0 were 
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tied, and the Prolene® 4-0 sutures of the second suture 
were tied as well.
Finally, the prosthesis should be inspected for 
distortions and to observe the contact surface between the 
leafl ets of the prosthesis, which is important to prevent 
the regurgitation of blood into the ventricular cavity. 
During the surgery, the lef t chambers were 
decompressed using an aspirator positioned in the left 
ventricle through the right superior pulmonary vein, 
which also helped to remove the air after the declamping 
of the aorta. 
Once this step was fi nished, we proceeded to close the 
aortotomy and fi nished the surgery in the usual way. 
All the surgeries were performed by the same surgeon 
and the same team. 
During the surgery, cardiopulmonary bypass and 
myocardial anoxic time were assessed (clamping of the 
aorta), and in the early postoperative period we assessed 
major clinical morbidities, such as the presence of 
myocardial infarction, stroke, renal failure, hemorrhage, 
orotracheal intubation time and length of ICU stay. All 
patients were submitted to a transthoracic echocardiogram 
during hospital stay, and this was compared with the one 
performed preoperatively.
Echocardiographic variables analyzed pre and 
postoperatively were: the maximum gradient pressure 
between the left ventricle and the aorta, the ventricular 
mass index and the left ventricle ejection fraction, in 
addition to the presence and degree of insuffi ciency of 
the prosthesis. 
Statistical study - We calculated the mean and 
standard deviation for continuous variables. Wilcoxon test 
was applied to compare two dependent or paired samples 
in time for the same patients. Alpha values < 0.05 or % 
were considered signifi cance levels. 
RESULTS
Associated procedures were performed in fi ve patients 
(20%): two were submitted to myocardial revascularization 
(one had a graft of the left internal thoracic artery into the 
anterior interventricular artery and [a graft] of the greater 
saphenous vein from the aorta to the fi rst diagonal branch, 
and the other received a saphenous vein graft from the 
aorta to the right coronary); one patient was submitted to 
mitral comissurotomy and to plasty of the tricuspid valve 
- the De Vega procedure - and two other patients had their 
mitral valves replaced with biological prosthesis.
As regards the diameter of stentless bioprostheses, 
we used one n. 21, four n. 23, ten n. 25, four n. 27 and 
one n. 29. As regards the mean time of cardiopulmonary 
bypass and of myocardial anoxia they were respectively 
136.5 ± 24.41 and 105.20 ± 21.62 minutes.
Hospital mortality was 5% (one patient). This patient, 
in addition to valve replacement, was submitted to 
myocardial revascularization and in the early postoperative 
period presented a major bleeding from a branch of the 
saphenous vein, which caused a hemorrhagic shock and 
cardiorespiratory arrest. Despite emergency thoracotomy 
and reanimation manouvers, the patient progressed to 
anoxic encephalopathy, prolonged intubation, respiratory 
failure, and eventually died on day 15 postoperatively due 
to multiple organ failure.
There was no case of perioperative infarction or elec-
trocardiographic alterations suggestive of myocardial 
ischemia.
Two patients (10%) had to be reoperated due to 
postoperative hemorrhage (these underwent associated 
procedures): one due to coagulapathy and the other due 
to bleeding of a saphenous vein branch; this last one died 
as has been previously described.
Postoperative hemorrhage varied from 140 to 4,150 
ml, with a mean of 766.8 ± 584.8 ml. Patients remained 
on average 3.65 ± 3.23 days in the ICU, and the mean 
orotracheal intubation time was 18 hours.
As regards respiratory complications, pulmonary 
infection was diagnosed in four patients. As regards 
the thoracic wall, one patient (5%) presented skin and 
subcutaneous dehiscence, and no case of postoperative 
mediastinitis was diagnosed in this series.
As regards other clinical complications, three (15%) 
presented acute atrial fi brillation; two patients underwent 
chemical cardioversion, and one underwent electrical 
cardioversion. One patient (5%) developed acute renal 
failure and required temporary dialytic treatment. 
All patients were submitted to bidimensional 
echocardiographic study before hospital discharge. 
When the ecocardiographic studies performed in the 
preoperative period were compared with those of the early 
postoperative period, we observed that mean transvalvular 
gradients were 82.61 ± 16.76 mmHg preoperatively 
and 25.39 ± 7.82 mmHg postoperatively, as shown in 
Fig. 1 – Stentless prosthesis being lowered to the aortic annulus.
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graph 1. Left ventricle ejection fraction was 67 ± 13.49% 
preoperatively and 63.24 ± 16.06% postoperatively. 
As regards left ventricle mass, the mean observed was 
245.5 ± 132.2 g preoperatively and 220.3 ± 104.3 g 
postoperatively, with p = 0.27. 
insufficiency7. In these cases the root replacement 
technique is an option14. 
As regards indications, stentless bioprostheses may be 
used in cases where biological prostheses are normally 
used, especially in elderly patients and young patients 
with a counter-indication for anticoagulation. 
In the literature there are studies showing that stentless 
bioprostheses are strongly indicated for those patients with 
severe aortic valve disease associated with left ventricular 
dysfunction15 and in the cases of small aortic annulus1,16. 
This is due to the fact that its internal diameter is larger 
than those of conventional prostheses and allows, in the 
postoperative period, signifi cantly lower gradient between 
the left ventricle and the aorta, thus facilitating the work 
of the left ventricle and favoring its recovery17. 
In this study, stentless bioprostheses were implanted 
using the subcoronary technique with morbidity and 
mortality similar to those described in the literature. 
Mortality was 5%, and the cause of death was bleeding 
of a saphenous vein branch in a patient submitted to an 
associated procedure, i.e. myocardial revascularization. 
This percentage corresponds to that described in the 
international literature for similar surgeries17-21.
Mean cardiopulmonary bypass and myocardial anoxic 
times, respectively 136.5 ± 24.41 and 105.2 ± 21.62 
minutes, are compatible with those described in the 
literature22,23, since the implant of stentless prostheses 
may be more time-consuming, as two suture planes are 
required; in this casuistics, fi ve patients (25%) were 
submitted to associated procedures for myocardial 
revascularization or mitral valve replacement. Although 
the implant of stentless bioprostheses takes longer, this 
could not be considered an independent risk factor24.
As regards early postoperative mediastinal bleeding, 
the mean observed was 766.8 ± 584.8 ml within 48 
hours or more, and fi ve patients presented bleeding in 
excess of 1,000 ml, of which four had been submitted 
to associated procedures for myocardial revascularization 
or mitral valve replacement, and had anoxic and 
cardiopulmonary bypass times greater than 120 minutes, 
which may account for the greater bleeding. Two patients 
(10%) had to be reoperated: one of them had a diagnosis 
of coagulopathy, and the other had hemorrhage coming 
from a saphenous vein branch, this latter patient being the 
one who eventually died in the ICU as described above. 
As regards mean extubation time and length of stay 
in the ICU, which were respectively 18 hours and 3.3 ± 
3.23 days, we believe that these times are compatible 
with the mean age of the patients operated and with the 
type of procedure performed. 
The mean gradient between the left ventricle and 
the aorta, assessed postoperatively on transthoracic 
echocardiography was 25.39 ± 7.82 mmHg, slightly 
higher than the gradients described in the world literature. 
Studies have been published demonstrating gradients as 
low as 10 to 15 mmHg at rest19,25,26, with no alteration 
with exercise27, and very similar to those observed when 
Graph 1 – Maximum aortic transvalvular gradient (mmHg) 
preoperatively and postoperatively.
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As regards prosthesis insuffi ciency, eleven patients 
did not present any degree of valve regurgitation eight 
presented mild regurgitation and one presented moderate 
to severe regurgitation on echocardiogram.
DISCUSSION
The first successful implant of stentless porcine 
bioprostheses using the subcoronary technique was 
performed by Sievers et al9 in 1985, in a patient with 
aortic stenosis.
The anatomy of stentless bioprostheses is very similar 
to the anatomy of the aortic valve, and the rationale for its 
use was the idea of using the aorta wall itself for support, 
where the prostheses cuspids will be sutured6. 
There are basically three types of surgery techniques 
for implant of these bioprostheses, and the most widely 
used method, which was used with all the patients of this 
study was subcoronary implant. The other techniques are 
the replacement of the aorta root and the inclusion (mini 
root) technique. Both of these are more complicated as 
coronary ostia have to be reimplanted, which may extend 
the time of cardiopulmonary bypass10.
In subcoronary implant, two lines of suture are 
performed: the fi rst on the subannular level, with separate 
stitches and the other on the continuous subcoronary 
level, around the inferior part of the coronary ostia11,12.
In the literature there is evidence in favor of this 
technique, such as the lower incidence of bleeding, 
shorter time of myocardial ischemia, lower risk of 
reoperation and lower incidence of valve insuffi ciency13. 
However, it requires knowledge of the spacial relationships 
of the aortic annulus and its relationships with adjacent 
structures, and this technique cannot be used in the 
cases where there is dilation and when the diameter of 
the aortic annulus is disproportional to the sinotubular 
junction, as this represents considerable risk of valve 
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cryopreserved homografts are used28,29, which directs our 
attention to the use of these prostheses, as they show 
to have better hemodynamic performance and favor the 
reduction of myocardial hypertrophy and the improvement 
of ventricular function30,31. A possible explanation for the 
obtainment of slightly lower gradients than those reported in 
the literature may lie in the differences between the different 
models of stentless bioprostheses available on the market32. 
In this study, we used Braile Biomédica®’s bioprostheses 
which are fi tted with a thin ring in their base and which 
may account for the higher gradient observed.
Additionally, in the literature, the most widely used 
prosthesis was the porcine one, whereas in this study we 
used the one made with bovine pericardium, which may 
also infl uence the higher gradient observed. 
In this study, the reduction of ventricular mass was 
not signifi cant because only the immediate postoperative 
period was analyzed. Randomized studies show that 
ventricular mass reduction may occur faster when stentless 
bioprostheses33 are used, with no difference, however, as 
regards other prostheses in the long term23,26,34. 
A frequent concern following the implant of stentless 
prostheses is the possibility of valve insuffi ciency due to 
the distortion of commissural posts. In this study, eight 
patients (40%) presented mild regurgitation and only 
one (5%) presented mild to moderate regurgitation. It is 
important to observe the aspect of the prosthesis after 
the implant, checking the leafl et coaptation surface, as 
this contact may prevent the regurgitation of blood into 
the ventricular cavity. Some authors recommend the use 
of intraoperative echocardiography to detect and assess 
prosthesis insuffi ciency and the presence of paravalvular 
insuffi ciency (leak)10. This is, by the way, more rare when 
two suture lines are used as we did in this study. 
As regards the other comorbidities found in the 
period analyzed, atrial fi brillation in three patients(15%), 
ischemic stroke in two (10%), and pulmonary infection 
in four (20%), the authors believe that they are within 
the values reported in the literature and are in agreement 
with the age range of patients and with the procedure 
carried out. They certainly contributed to a longer stay 
at the ICU and in hospital, but had no impact on the 
immediate mortality or on the hemodynamic performance 
of the prostheses implanted.
Follow-up studies carried out fi ve, eight and ten years 
after the implant of stentless bioprostheses showed 
excellent results in terms of prosthesis durability, in 
addition to the advantages already known, such as: low 
gradients of the left ventricular outfl ow tract, large effective 
valve orifi ce and regression of ventricular mass22,35,36. 
We conclude that stentless bovine pericardium 
bioprotheses can be used to surgically treat aortic valve 
diseases with hospital morbidity and mortality similar 
to those described in the literature for other types of 
prostheses and that their hemodynamic performance is 
satisfactory, with a low rate of prosthesis insuffi ciency 
and low transvalvular gradient.
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